Obesity is multifactorial. The response must be too.

For decades, obesity was framed as a problem of willpower — a misalignment between calories consumed and calories expended. That framing has steadily eroded. Modern clinical practice now recognises obesity as a multifactorial chronic disease, in line with positions adopted by the WHO, NICE, IFSO, and an increasing number of national health authorities. The implications for clinical decision-making are substantial: an approach focused on a single lever — diet alone, exercise alone, surgery alone, or medication alone — tends to underperform over the long term, because it addresses only one slice of a much broader physiological and behavioural picture.

Appetite regulation, in particular, draws on a long list of physiological pathways that interact, overlap, and sometimes compensate for one another. The hormonal pathways involve gut peptides such as GLP-1, leptin, ghrelin, PYY, CCK, and others — each with its own receptors, timing, and integration with central appetite control. The metabolic pathways include insulin signalling, insulin resistance, and the downstream effects on fuel partitioning. The anatomical pathways relate to gastric volume, intestinal transit, and the structural conditions that shape satiety. The behavioural pathways span cognitive, emotional, and social dimensions of eating. Genetic predisposition, environmental cues, gut microbiota composition, and neuro-inflammatory mechanisms all add further layers — and other pathways may yet need to be better characterised in the years ahead. This page focuses on two of these pathways — without claiming they are the only ones, or even the most important ones in every clinical situation.

Why these two in particular? The neuro-hormonal pathway is the one currently carried into mainstream clinical conversation by GLP-1 receptor agonists, whose rapid adoption has reshaped how physicians think about pharmacological obesity care. The mechanosensorial pathway has been comparatively neglected for decades, despite the foundational physiological work of Paintal in 1954, Geliebter in 1986, and Phillips & Powley in 1998. It is now being revisited as a clinically actionable lever. These two pathways stand out today because they are the most actionable through interventions currently available or emerging — and because they act through fundamentally different upstream mechanisms.

It bears repeating: none of what follows replaces the other dimensions of obesity care. Dietary follow-up, behavioural and psychological support, adapted physical activity, bariatric surgery for eligible profiles, and sustained medical follow-up remain core elements of any integrated pathway. The two pathways explored below are levers within a broader care framework, not stand-alone solutions.

Why physicians value the complementarity

In day-to-day clinical practice, the rationale for complementarity between GLP-1 therapies and the mechanosensorial approach is increasingly part of the clinical conversation. Because obesity is multifactorial, any single-lever approach carries built-in limitations. The complementarity between the two pathways is now clinically discussed as a practical avenue worth documenting — not as an established therapeutic doctrine, but as a working hypothesis being characterised through ongoing data collection.

On the first level — supporting overall outcomes — GLP-1 therapies do most of the heavy lifting for many patients during the active phase of treatment. But durability remains a substantial challenge: the post-discontinuation curve in published extension studies is hard to ignore. Adding a mechanical lever during the active phase may help patients focus on mechanical satiety signals during meals, potentially supporting smaller portions and behavioural adherence. It may also start to prepare the patient for what comes after the pharmacological window closes — whether that closure happens at three months, twelve, or twenty-four.

On a second and perhaps more distinctive level, the mechanosensorial pathway opens the door to something pharmacology cannot easily deliver: a clinical hypothesis some physicians describe as retraining the physical sensations of satiety. One of the under-discussed phenomena associated with years or decades of disordered eating patterns is a possible desensitisation of mechanical satiety perception. Patients with overweight or obesity often describe not feeling fullness arrive at the right moment, which may sustain larger portions and weaken the natural braking system of the meal. Engaging the mechanosensorial pathway repeatedly, meal after meal, is hypothesised to support a perceptual relearning: the patient may re-learn to recognise the mechanical signature of satiety. The objective is to support an interoceptive learning that may persist beyond the active use period — though the magnitude and persistence of this learning remain under clinical documentation. The contrast with pharmacological effects, which are by design conditional on continued administration, is mechanistic. There is a clinical timing argument here: using GASTER control® during the pharmacological window may allow consolidation of a perceptual competence that could remain available to the patient when treatment ends. The concept some clinicians describe as building back interoception is the framing in which this rationale is being explored.

On a third level, the complementarity has potential relevance across multiple moments of the care pathway: alongside an active GLP-1 treatment as a mechanistic complement; as a possible relay after discontinuation, when the pharmacological effect fades; and outside the GLP-1 prescription perimeter altogether — for the very large population of patients who do not access GLP-1 therapy because of clinical, economic, or geographical constraints. These three moments are not theoretical: they map to clinical situations that physicians encounter constantly in current practice. The question of which intervention to integrate, when, and in what sequence remains a clinical judgement that belongs to the dialogue between patient and physician.

The following section translates these observations into four concrete clinical scenarios where the question of complementarity legitimately arises. The observational registry GC-REG-01 is designed precisely to document how these scenarios play out in real-world conditions, and the data collected will progressively sharpen the clinical positioning of the device within integrated care pathways.

What current data show, and what we are building

The current evidence base for GASTER control® is preliminary. We share that openly. An initial single-centre exploratory study on a small cohort (n=11, over 8 weeks, conducted by Dr Rouers) reported encouraging signals on indicators of perceived satiety and behavioural adherence. These early data should be read as a foundation rather than as a definitive demonstration of efficacy. We share them not as proof, but as the empirical starting point for the larger studies that follow. A consolidated view of the clinical evidence for mechanical satiety modulation is available on the dedicated page.

The core of our current evidence work is GC-REG-01, a prospective multicentre observational registry. Its purpose is to document, in real-world clinical conditions, how the complementarity between GLP-1 therapies and the mechanosensorial pathway plays out across the four scenarios outlined above. The registry's recruitment target is 50–80 patients across multiple investigator centres in France, with Dr Rouers as initial investigator and Dr Lanne joining the investigator network following the SOFFCO.MM 2026 congress. The protocol is observational by design — it documents practice rather than constraining it — and the dataset will progressively allow more precise positioning of GASTER control® within integrated care pathways.

GASTER control® was presented at the SOFFCO.MM 2026 congress in Marseille (Parc Chanot, 21–22 May 2026), where the approach generated clinical discussions and helped expand the investigator network through new clinical contacts. The post-congress dynamic has been a useful pulse-check: the framing of multimodal complementarity resonates with clinicians who are actively searching for tools to consolidate the gains of GLP-1 therapy and to address the access gaps that remain. A detailed account of the five insights emerging from the congress is available in our SOFFCO.MM 2026 recap.

Importantly, this approach is part of a broader clinical movement, not an isolated initiative. The IFSO-EC 2024 GRADE-based recommendations have formally endorsed multimodal approaches in the context of bariatric obesity care. Recent clinical recommendations increasingly support integrated, layered approaches in obesity care, particularly where single-lever strategies do not address the full complexity of long-term weight management. The work we are doing on the mechanosensorial pathway sits within this broader movement.

On the horizon: a manuscript is in preparation for submission to BMJ Open, the investigator network continues to expand, and we maintain an open posture of dialogue with the clinical community. The data we collect — and the limits of those data — will be communicated transparently as they accumulate.

Frequently asked questions

Last updated: June 17, 2026  ·  Page type: educational reference (informational, non-promotional)